Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Background Lung cancer is characterized by high morbidity and mortality due to the lack of practical early diagnostic and prognostic tools. The present study uses machine learning algorithms to construct a clinical predictive model for non-small cell lung cancer (NSCLC) patients. Methods Laboratory indices of the NSCLC patients at their initial visit were collected for quality control and exploratory analysis. By comparing the levels of the above indices between the survival and death groups, the statistically significant indices were selected for subsequent machine learning modeling. Ten machine learning algorithms were then employed to develop the predictive models with survival and recurrence as outcomes, respectively. Moreover, regression models were constructed using the random survival forest algorithm by incorporating the survival time dimension. Finally, critical variables in the optimal model were screened based on the interpretable algorithms to build a decision tree to facilitate clinical application. Results 682 patients were enrolled according to the inclusion and exclusion criteria. The preliminary comparison results revealed that except for fast blood glucose, CD 3 + T cell proportion, NK cell proportion, and CA72-4, there were significant statistical differences in other tumor markers, inflammation, metabolism, and immune-related indices between the survival and death groups ( p < 0.01). Subsequently, indices with statistical differences were incorporated into machine learning modeling and evaluation. The results showed that among the ten prognostic models constructed using survival status as the outcome, the neural network model obtained the best predictive performance, with accuracy, sensitivity, specificity, AUC, and precision values of 0.993, 0.987, 1.000, 0.994, and 1.000, respectively. The corresponding SHAP16 algorithm revealed that the top five variables in terms of importance were interleukin6 (IL-6), soluble interleukin2 receptor (sIL-2R), cholesterol, CEA, and Cy211, respectively. The random survival forest model also confirmed the critical role of CEA, sIL-2R, and IL-6 in predicting the prognosis of NSCLC patients. A decision tree model with seven cut-off points based on the above three indices was eventually built for clinical application. Conclusion The neural network model exhibited ideal predictive performance in the survival status of NSCLC patients, and the decision tree model constructed based on selected important variables was conducive to rapid bedside prognosis assessment and decision-making. Supplementary Information The online version contains supplementary material available at 10.1186/s12911-024-02753-3.
Background Lung cancer is characterized by high morbidity and mortality due to the lack of practical early diagnostic and prognostic tools. The present study uses machine learning algorithms to construct a clinical predictive model for non-small cell lung cancer (NSCLC) patients. Methods Laboratory indices of the NSCLC patients at their initial visit were collected for quality control and exploratory analysis. By comparing the levels of the above indices between the survival and death groups, the statistically significant indices were selected for subsequent machine learning modeling. Ten machine learning algorithms were then employed to develop the predictive models with survival and recurrence as outcomes, respectively. Moreover, regression models were constructed using the random survival forest algorithm by incorporating the survival time dimension. Finally, critical variables in the optimal model were screened based on the interpretable algorithms to build a decision tree to facilitate clinical application. Results 682 patients were enrolled according to the inclusion and exclusion criteria. The preliminary comparison results revealed that except for fast blood glucose, CD 3 + T cell proportion, NK cell proportion, and CA72-4, there were significant statistical differences in other tumor markers, inflammation, metabolism, and immune-related indices between the survival and death groups ( p < 0.01). Subsequently, indices with statistical differences were incorporated into machine learning modeling and evaluation. The results showed that among the ten prognostic models constructed using survival status as the outcome, the neural network model obtained the best predictive performance, with accuracy, sensitivity, specificity, AUC, and precision values of 0.993, 0.987, 1.000, 0.994, and 1.000, respectively. The corresponding SHAP16 algorithm revealed that the top five variables in terms of importance were interleukin6 (IL-6), soluble interleukin2 receptor (sIL-2R), cholesterol, CEA, and Cy211, respectively. The random survival forest model also confirmed the critical role of CEA, sIL-2R, and IL-6 in predicting the prognosis of NSCLC patients. A decision tree model with seven cut-off points based on the above three indices was eventually built for clinical application. Conclusion The neural network model exhibited ideal predictive performance in the survival status of NSCLC patients, and the decision tree model constructed based on selected important variables was conducive to rapid bedside prognosis assessment and decision-making. Supplementary Information The online version contains supplementary material available at 10.1186/s12911-024-02753-3.
Background: Recent research has revealed a correlation between serum bilirubin levels and cancer risk and mortality. This study explored the potential of bilirubin as a significant predictor of the therapeutic efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs) in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Methods: This multicenter cohort study included patients diagnosed with EGFR-mutated NSCLC and treated with EGFR-TKIs (discovery cohort, n = 113; validation cohort, n = 53). Serum direct bilirubin (DBIL) was measured before and 3–4 months after treatment. Patients were categorized into DBILlow and DBILhigh groups around the median DBIL and DBILin or DBILde groups according to whether DBIL increased or decreased after treatment. Results: Multivariate Cox regression analysis of the discovery cohort revealed that smoking (HR, 1.4357; 95% CI, 1.0459–10.9709; p = 0.0253) and DBIL (HR, 1.3006; 95% CI, 1.0054–1.6824; p = 0.0454) were independent risk factors for overall survival (OS). Kaplan–Meier analysis revealed significantly shorter OS in the DBILhigh (p = 0.0273) and Smoking+ (p < 0.001) groups. When these factors were combined, the DBILhigh Smoking+ group had the shortest OS, whereas the DBILlow Smoking− group had the longest OS (p = 0.0011). This trend was consistent with that in the validation cohort (p = 0.0449). Additionally, the DBIL level did not significantly change in the survival group (p = 0.3208, p = 0.1204), whereas the post-treatment DBIL level significantly increased in the nonsurviving group (p = 0.0457, p = 0.0297) in both cohorts. The DBILin group demonstrated shorter OS in both cohorts (p = 0.0229 and p = 0.0424, respectively). Conclusions: Serum DBIL and smoking status were significant biomarkers for prognosis in EGFR-mutated NSCLC patients receiving EGFR-TKI therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.